Orally Disintegrating Tablet Market Size, Share & Trends Analysis Report By Drug Class (Analgesics, Anti-psychotics, Anti-epileptics, Gastro-intestinal Drugs, Anti-hypertensive Drugs, Others), By Technology (Conventional, Freeze Drying, Floss-based Technology), By Distribution Channel (Hospital Pharmacies, Drugs Stores & Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Orally Disintegrating Tablet Market Size

The global orally disintegrating tablet market size was valued at USD 15.85 billion in 2025 and is projected to grow from USD 17.02 billion in 2026 to USD 30.08 billion by 2034, registering a CAGR of 7.38% during the forecast period from 2026 to 2034. North America dominated the orally disintegrating tablet market with a market share of 38.4% in 2025.

An orally disintegrating tablet (ODT) is a type of medication that quickly dissolves or disintegrates in the mouth without the need for water. It is designed to dissolve on the tongue within seconds, making it easier for individuals who may have difficulty swallowing pills, such as children or elderly patients. ODTs are commonly used for medications that treat conditions like nausea, pain, or allergies. The unique formulation of ODTs helps ensure that the active ingredient is rapidly absorbed into the bloodstream, providing quicker relief.

Several key factors are driving the growth of the ODT market. The increasing prevalence of chronic diseases, including mental health disorders, gastrointestinal issues, hypertension, and others, is creating a demand for more accessible drug delivery options. Moreover, advancements in research and development of novel drug delivery systems are boosting innovation within the market. Rising healthcare investments, coupled with growing patient awareness and compliance, further contribute to this expansion.

Drug Class Insights

The antipsychotics segment holds the largest market share, driven by the rising prevalence of mental health disorders and the increasing demand for easier-to-administer medications. Research and development efforts are fueling the launch of new ODT products tailored for mental health treatment, further solidifying this segment’s dominance. According to the Institute for Health Metrics and Evaluation, 13.9% of the global population experienced mental health disorders in 2021, underscoring the growing need for accessible treatment options.

Request Customizationto receive a tailored report.

Technology Insights

The conventional segment leads the market, primarily due to the cost-effectiveness and simplicity of methods like dry granulation, wet granulation, and direct compression. These processes do not require specialized equipment or conditions, making them highly efficient and adaptable for mass production. The flexibility to switch platforms based on formulation components also contributes to the popularity of conventional technologies among manufacturers, reinforcing its dominance in the ODT market.

Distribution Channel Insights

Hospital pharmacies dominate the distribution of ODTs, particularly for conditions that require specialized care, such as mental health disorders, severe hypertension, gastrointestinal issues, and seizures. These diseases often necessitate hospitalization, where hospital pharmacies play a critical role in providing timely access to medications. Their essential position in the healthcare system as the primary distribution channel for these treatments leads to the hospital pharmacies segment commanding the largest market revenue.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America leads the global orally disintegrating tablet market, capturing the largest revenue share. This dominance is driven by significant investments in research and development, as well as a high prevalence of chronic conditions such as mental health disorders, hypertension, and gastrointestinal diseases.

• For example, according to the Centers for Disease Control and Prevention (CDC), between 2021 and 2023, nearly 48% of U.S. adults were affected by hypertension, with the incidence rising to 70% among adults aged 60 and above.

The need for long-term medication management for conditions like hypertension is fueling the demand for convenient drug delivery options, such as ODTs, which require no water and are easier to administer. This growing need for ODTs is contributing to the overall market expansion in North America.

The U.S. remains a market leader due to strong investments in research and development and a high prevalence of chronic diseases. With the launch of novel ODT products addressing various health conditions, continuous innovation is key. For instance, in December 2024, MindMed began Phase 3 trials for MM120 ODT, a treatment for generalized anxiety disorder (GAD), a significant step toward offering optimized treatments in the mental health space.

Canada's ODT market is expanding, driven by the need for more accessible treatments for chronic disease patients. Market players are boosting their portfolios with new product launches, thus meeting the rising demand. For example, in April 2022, Pharmascience Canada launched pms-Ondansetron ODT, a generic drug available in 4 mg and 8 mg doses, providing crucial relief for patients with nausea due to various medical conditions.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia-Pacific Orally Disintegrating Tablet Market Trends

Asia-Pacific is projected to witness the fastest CAGR during the forecast period, owing to factors such as rising cases of chronic diseases, growing healthcare awareness, and increasing product launches in various countries with continuous research and development. For instance, in June 2024, HK inno.N launched K-CAB ODT 25 mg for treatment of Gastrointestinal Reflux Disease (GERD). It is the only product with ODT formulation and indication for maintenance therapy among P-CAB class products released in Korea.

Japan's ODT market is booming, with continuous new product launches and strong pharmaceutical industry growth. Innovation through research and development is key to expanding product portfolios. For instance, in May 2022, Daiichi Sankyo launched Minnebro ODT, an antihypertensive agent. The country's growing demand for convenient medications is fueling the expansion of the ODT market, making it a key growth region.

China’s ODT market is expanding rapidly, supported by increased investment in research and development, enhanced manufacturing facilities, and favorable regulatory frameworks. The market is benefiting from the approval of new treatments like Toray's REMITCH Nalfurafine Hydrochloride ODT, which was approved by China’s NMPA in July 2023 for pruritus relief. These advancements are contributing to the steady growth of the healthcare sector, driving market development.

India's healthcare market is growing with significant investments in research, development, and manufacturing centers, creating more opportunities for ODT market growth. For example, in May 2022, DFE Pharma opened a center of excellence in India, offering fast-track formulation services. These services support the development of various specialized dosage forms, including ODTs, boosting the country’s market potential in the pharmaceutical sector.

Australia’s ODT market is flourishing due to the increasing demand for innovative and novel formulations. These advancements are improving patient compliance by offering more convenient medication options. For instance, in October 2024, Swisse Wellness launched a line of vitamins, minerals, and supplements in ODT form, further expanding the availability of ODT products in the Australian market and catering to a growing preference for easy-to-consume formulations.

Europe Orally Disintegrating Tablet Market Trends

Spain is witnessing significant growth in its ODT market, with well-established players launching innovative products. These efforts are expanding the ODT product offerings, catering to the increasing demand for convenient drug delivery. Faes Farma launched Bilastine ODT in 2023, an antihistamine that alleviates allergic symptoms, helping to address a key health concern while enhancing patient compliance.

The UK is becoming the dominant market for orally disintegrating tablets market, with an increasing number of major illness cases. The requirement for medications, as well as the launch of innovative products, drive the market growth. According to Health Foundation UK, in 2023, more than 2.5 million people in England are projected to be living with major illness by 2040. This increasing number indicates the demand and drives the market growth in the UK.

Company Market Share

Key players in the orally disintegrating tablet (ODT) market are actively investing in R&D and expanding their manufacturing capabilities to strengthen their product portfolios and increase market penetration. These companies are focused on developing innovative and optimized ODT formulations that cater to a wide range of therapeutic applications, including mental health, gastrointestinal disorders, and chronic conditions.

Kalvista Pharmaceuticals: An Emerging Provider in the Orally Disintegrating Tablet Market

KalVista Pharmaceuticals is an emerging player in the orally disintegrating tablet (ODT) market, known for its groundbreaking work in oral protease inhibitor drugs. The company leverages its deep expertise in the kallikrein-kinin system to develop novel treatments for various diseases, including those related to inflammation and vascular health.

List of Key and Emerging Players in Orally Disintegrating Tablet Market